Novartis AG

Open: 98.85 Close: 98.75 Change: -0.1

The best way to get informed about Novartis AG Stock without reading hundreds of pages.

This document will help you to evaluate Novartis AG without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Swiss, pharmaceutical, company, share, outstanding, …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG has 2.06 billion shares outstanding. Revenue per employee $514,469. Profits per employee are $77,048.

Today's News

Novartis AG has 2.06 billion shares outstanding. Revenue per employee $514,469. Profits Per Employee $77,048. Novartis AG (NVS) Stock Price, News, Quotes-Moomoo.com. novartis ag (nvs) stock price, news, quotes-moomoo. Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel. Novart is a publicly traded Swiss holding company that owns, directly or indirectly, all companies that operate as subsidiaries of the Novarti Group. In 1996, Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together. Novartis applied for Exclusive Marketing Rights (EMR) for Gleevec from the Indian Patent Office in 2003. In 2010, a jury awarded $3,367,250 in compensatory damages for sexual discrimination against 12 female sales representatives and entry-level managers since 2002. Novartis has been committed for decades to eliminate Leprosy by providing free, multidrug therapy to all endemic countries since 2000. AveXis voluntarily disclosed to the FDA that some data submitted to the agency as part of the Biologics License Application was inaccurate.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, Swiss, pharmaceutical, company, share, outstanding, and the most common words in the summary are: novartis, stock, market, company, ag, news, option, . One of the sentences in the summary was: Novartis AG has 2.06 billion shares outstanding. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #stock #market #company #ag #news #option.